Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Klonopin expiration date?Adderall xr generic price?Generic for atenolol?Pmda doxazosin mesylate alpha1 blocker hypertension package insert?Trospium chloride u's approval date?
See the DrugPatentWatch profile for Jornay
Jornay PM received FDA approval on January 23, 2020 [1].
The patent and exclusivity landscape for Jornay PM is complex. While the initial FDA approval date is known, information regarding when market exclusivity ends is subject to patent challenges and regulatory considerations. DrugPatentWatch.com tracks these developments, providing data on patent expiry and potential generic entry dates [2].
Jornay PM is a methylphenidate hydrochloride extended-release medication indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in individuals 6 years of age and older [1]. It is a novel formulation designed to deliver medication at different times throughout the day.
Jornay PM is a stimulant medication. It works by affecting the balance of certain natural substances in the brain called neurotransmitters. By increasing the levels of dopamine and norepinephrine, it can help improve focus, attention, and impulse control [1]. The extended-release mechanism is designed to provide symptom control throughout the day and into the evening.
Other Questions About Jornay :